![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
Abstract
Purpose: To evaluate the outcomes of the Ex-PRESS Filtration Device in patients with uveitic glaucoma.
Methods: We reviewed 23 eyes, comparing control simple glaucoma patients (n = 11) to uveitic glaucoma patients (n = 12). Intraocular pressure (IOP) and glaucoma medications at the preoperative examination were compared with those at the 6-month and 10–14-month postoperative examination. Surgical success was defined as ≥25% decrease in intraocular pressure without hypotony, and/or decrease in glaucoma medications at 6 months follow-up.
Results: Statistically significant reduction in mean IOP from preoperative levels occurred in both groups at 6 months follow-up (p<0.0001) and 10–14 months follow-up (p = 0.0007) and in the mean number of medications in the uveitic glaucoma (UG) group (p = 0.0313).
Conclusions: Surgical success was seen in 10 eyes in the control group (90.9%) and nine eyes (75%) in the UG group (p = 0.314). Ex-PRESS implantation is an effective surgical intervention for the management of uveitic glaucoma.
ACKNOWLEDGMENTS
SD, NCK, ARP, CF and JP contributed to the conception, design, acquisition of data and drafting this article. CS Foster was responsible for critically reviewing the intellectual content of the article. All authors read and approved the final manuscript. The authors alone are responsible for the content and writing of the paper.
DECLARATION OF INTEREST
The authors have no conflicting interest in the products mentioned in this manuscript. CSF discloses: Consultancies with Aldeyra Therapeutics (Lexington, MA), Bausch & Lomb Surgical, Inc (Rancho Cucamonga, CA), Eyegate Pharma (Waltham, MA), Novartis (Cambridge, MA), and pSivida (Watertown, MA). Grants or grants pending with Alcon (Aliso Viejo, CA), Aldeyra Therapeutics (Lexington, MA), Bausch & Lomb (Bridgewater, NJ), Clearside Biomedical (Alpharetta, GA), Dompé Pharmaceutical (Milan, Italy), Eyegate Pharma (Waltham, MA), Mallinckrodt pharmaceuticals (Dublin, Ireland), Novartis Pharmaceuticals (Cambridge, MA), pSivida (Watertown, MA), Santen (Osaka, Japan). Remuneration for lectures, including service on speaking bureaus: Alcon (Aliso Viejo, CA), Allergan (Dublin, Ireland). Stock or Stock Options: Eyegate Pharma (Waltham, MA).
SD had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the analysis.
ARP takes responsibility for the Independent Statistical Analysis
The information herein was given in a previous presentation(s): Poster presentation of the abstract at the Association for Research in Vision and Ophthalmology 2014 in Orlando, FL and at the New England Ophthalmological Society 2014 in Boston, MA.
All other authors report no conflicts of interest.